MEDICAL ONCOLOGY

CLOSED TO RECRUITMENT — AUSTRALIA

Abbrev. Title

Protocol Title

CL-SBP-101-03 CLSBP-101-03 A Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination with Nab-Paclitaxel and Gemcitabine in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

CN1-101 A Phase I, Open Label, Multi-Center, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 in Patients with Advanced Solid Tumours or B-cell Lymphoma

CO39303 IPATential150 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

CO41101 IPATunity170 A Phase III, Double-Blind, Placebo-Controlled, Randomized Study of Ipatasertib in Combination with Atezolizumab and Paclitaxel as a Treatment for Patients with Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

COGNO 16 01 NUTMEG A Randomized Phase II Study of Nivolumab and Temozolomide Vs Temozolomide in Newly Diagnosed Elderly Glioblastoma

CPI 0610-04 MANIFEST-2 A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

CP-MGA271-06 NORTH A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination with Retifanlimab or Tebotelimab in the First-Line Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

CS1002-101 A Phase Ia/Ib, Open-Label, Dose-Escalation and Dose-Expansion Study of the Anti-CTLA4 Monoclonal Antibody as Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody in Subjects with Advanced Solid Tumours

CS1003-101 A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumours

CTC0160 EMBRACE Phase 2 Clinical Trial of the PARP Inhibitor, Olaparib, in HR-deficient Metastatic Breast and Relapsed Ovarian Cancer in Patients without Germline Mutations in BRCA1 and BRCA2